Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol use. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. METHODS: We conducted a multicenter, double-blind, randomized trial with a 2-by-2 factorial design to evaluate the effect of treatment with prednisolone or pentoxifylline. The primary end point was mortality at 28 days. Secondary end points included death or liver transplantation at 90 days and at 1 year. Patients with a clinical diagnosis of alcoholic hepatitis and severe disease were randomly assigned to one of four groups: a group that received a pentoxifylline-matched placebo and a prednisolone-matched placebo, a group that received prednisolone and a pentoxifylline-matched placebo, a group that received pentoxifylline and a prednisolone-matched placebo, or a group that received both prednisolone and pentoxifylline. RESULTS: A total of 1103 patients underwent randomization, and data from 1053 were available for the primary end-point analysis. Mortality at 28 days was 17% (45 of 269 patients) in the placebo-placebo group, 14% (38 of 266 patients) in the prednisolone-placebo group, 19% (50 of 258 patients) in the pentoxifylline-placebo group, and 13% (35 of 260 patients) in the prednisolone-pentoxifylline group. The odds ratio for 28-day mortality with pentoxifylline was 1.07 (95% confidence interval [CI], 0.77 to 1.49; P=0.69), and that with prednisolone was 0.72 (95% CI, 0.52 to 1.01; P=0.06). At 90 days and at 1 year, there were no significant between-group differences. Serious infections occurred in 13% of the patients treated with prednisolone versus 7% of those who did not receive prednisolone (P=0.002). CONCLUSIONS: Pentoxifylline did not improve survival in patients with alcoholic hepatitis. Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. (Funded by the National Institute for Health Research Health Technology Assessment program; STOPAH EudraCT number, 2009-013897-42 , and Current Controlled Trials number, ISRCTN88782125 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Corticosteroid therapy of alcoholic hepatitis
Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Mezey, E., & White, R. I. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90401-8 · Cited by 925
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Akriviadis, E., Botla, R., Briggs, W., Han, S., Reynolds, T., & Shakil, O. (2000) · Gastroenterology · doi:10.1053/gast.2000.20189 · Cited by 800
Mathurin, P., O'Grady, J., Carithers, R. L., Phillips, M., Louvet, A., Mendenhall, C. L., Ramond, M.-J., Naveau, S., Maddrey, W. C., & Morgan, T. R. (2011) · Gut · doi:10.1136/gut.2010.224097 · Cited by 455
Self-citationGlucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis
Nguyen-Khac, E., Thevenot, T., Piquet, M.-A., Benferhat, S., Goria, O., Chatelain, D., Tramier, B., Dewaele, F., Ghrib, S., Rudler, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1101214 · Cited by 410
A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis
Ramond, M.-J., Poynard, T., Rueff, B., Mathurin, P., Théodore, C., Chaput, J.-C., & Benhamou, J.-P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260802 · Cited by 392
Louvet, A., Wartel, F., Castel, H., Dharancy, S., Hollebecque, A., Canva–Delcambre, V., Deltenre, P., & Mathurin, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.062 · Cited by 367
Mathurin, P., Duchatelle, V, Ramond, M., Degott, C., Bedossa, P., Erlinger, S., Benhamou, J., Chaput, J., Rueff, B., & Poynard, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8964410 · Cited by 292
Cited by
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Self-citationCrabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
ACG Clinical Guideline: Alcoholic Liver Disease
Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.469 · Cited by 835
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease
Grander, C., Adolph, T. E., Wieser, V., Lowe, P., Wrzosek, L., Gyongyosi, B., Ward, D. V., Grabherr, F., Gerner, R. R., Pfister, A., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313432 · Cited by 618
Crabb, D. W., Bataller, R., Chalasani, N. P., Kamath, P. S., Lucey, M., Mathurin, P., McClain, C., McCullough, A., Mitchell, M. C., Morgan, T. R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.042 · Cited by 553
Acute-on-chronic liver failure in cirrhosis
Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U., García-Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 434
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review
Singal, A. K., & Mathurin, P. (2021) · JAMA · doi:10.1001/jama.2021.7683 · Cited by 398
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
“Even though the benefit of steroids in severe ASH has been questioned [87], a randomized controlled trial showed that mortality in severe ASH with total ENwas similar to that of severe ASH treatedwith steroids during 28 days.”
ResultOutcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis
Lee, B. P., Mehta, N., Platt, L., Gurakar, A., Rice, J. P., Lucey, M. R., Im, G. Y., Therapondos, G., Han, H., Victor, D. W., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.009 · Cited by 377
EASL Clinical Practice Guidelines on acute-on-chronic liver failure
Moreau, R., Tonon, M., Krag, A., Angeli, P., Berenguer, M., Berzigotti, A., Fernandez, J., Francoz, C., Gustot, T., Jalan, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.021 · Cited by 375
Acute-on-chronic liver failure: terminology, mechanisms and management
Sarin, S. K., & Choudhury, A. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.219 · Cited by 342
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis
China, L., Freemantle, N., Forrest, E., Kallis, Y., Ryder, S. D., Wright, G., Portal, A. J., Becares Salles, N., Gilroy, D. W., & O’Brien, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2022166 · Cited by 333
Self-citationAcute-on-chronic liver failure
Bernal, W., Jalan, R., Quaglia, A., Simpson, K., Wendon, J., & Burroughs, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00309-8 · Cited by 331
Lackner, C., Spindelboeck, W., Haybaeck, J., Douschan, P., Rainer, F., Terracciano, L., Haas, J., Berghold, A., Bataller, R., & Stauber, R. E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.011 · Cited by 293
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Bataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
Im, G. Y., Kim-Schluger, L., Shenoy, A., Schubert, E., Goel, A., Friedman, S. L., Florman, S., & Schiano, T. D. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13586 · Cited by 253
Pyroptosis by caspase11/4‐gasdermin‐D pathway in alcoholic hepatitis in mice and patients
Khanova, E., Wu, R., Wang, W., Yan, R., Chen, Y., French, S. W., Llorente, C., Pan, S. Q., Yang, Q., Li, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29645 · Cited by 228
Alcohol-associated liver disease—Global epidemiology
Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V. (2024) · Hepatology · doi:10.1097/hep.0000000000000899 · Cited by 163
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Mandrekar, P., Bataller, R., Tsukamoto, H., & Gao, B. (2016) · Hepatology · doi:10.1002/hep.28530 · Cited by 115
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Microbiota, a key player in alcoholic liver disease
Cassard, A.-M., & Ciocan, D. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0067 · Cited by 100
Inflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets
Feng, D., Hwang, S., Guillot, A., Wang, Y., Guan, Y., Chen, C., Maccioni, L., & Gao, B. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.04.009 · Cited by 44
Design of a multicenter randomized clinical trial for treatment of alcohol-associated hepatitis
Tu, W., Gawrieh, S., Dasarathy, S., Mitchell, M. C., Simonetto, D. A., Patidar, K. R., McClain, C. J., Bataller, R., Szabo, G., Tang, Q., et al. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101074 · Cited by 21
“They were similar to the recently published DASH trial [17], and broadly comparable to that of the STOPAH subjects [9], except that our participants were slightly younger with higher MELD and MDF scores.”
BackgroundResultYeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s165676 · Cited by 20
Metadata
- Authors
- Thursz, M. R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C. P., Downs, N., Gleeson, D., MacGilchrist, A., Grant, A., Hood, S., Masson, S., McCune, A., Mellor, J., O’Grady, J., Patch, D., Ratcliffe, I., Roderick, P., Stanton, L., Vergis, N., Wright, M., Ryder, S., & Forrest, E. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-23
- Volume
- 372
- Issue
- 17
- Pages
- 1619-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973630785
- Cited by
- 769
- References
- 18
- FWCI
- 50.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.